Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 2,990 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 2,990 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $41.26 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The stock has a market capitalization of $3.82 billion, a P/E ratio of -6.51 and a beta of 0.60. The stock’s fifty day moving average is $42.91 and its 200 day moving average is $49.10.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RARE. International Assets Investment Management LLC grew its position in Ultragenyx Pharmaceutical by 29,580.0% in the third quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 10,353 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Ultragenyx Pharmaceutical by 34.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 851 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Ultragenyx Pharmaceutical by 195.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $1,208,000 after acquiring an additional 14,394 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Ultragenyx Pharmaceutical by 9.9% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 429,302 shares of the biopharmaceutical company’s stock valued at $23,848,000 after acquiring an additional 38,778 shares during the last quarter. Finally, Emerald Advisers LLC grew its position in Ultragenyx Pharmaceutical by 17.1% in the third quarter. Emerald Advisers LLC now owns 569,798 shares of the biopharmaceutical company’s stock valued at $31,652,000 after acquiring an additional 83,116 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on RARE. Canaccord Genuity Group raised their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Wedbush reiterated a “neutral” rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. JPMorgan Chase & Co. lowered their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $93.50.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.